lundi 23 juillet 2018

Onco Actu du 23 juillet 2018

1. Biologie

Leukaemia follows a blood-vessel track to enter the nervous system [Nature]

1.1 Biologie - Gènes

A Close Look at a Cancer Genome [In the Pipeline]

1.4 Biologie - Technos

Potential DNA damage from CRISPR has been ‘seriously underestimated,’ study finds [STAT]

The safety of CRISPR-Cas9 gene editing is being debated [The Economist]

CRISPR gene editing produces unwanted DNA deletions [Nature]

2. Etiologie

Contagious cancer could have wiped out America's first dogs [Nature]

2.4 Etiologie - Portables, ondes e-m

Mobile phones and cancer – the full picture [The Guardian]

2.6 Etiologie - Environnement

The man who haunts Europe’s food safety watchdog [Politico]

UK accused of 'green Brexit hypocrisy' over regulation of suspected carcinogen [The Guardian]

EPA Stalls Release of Carcinogen Report [The Scientist]

3. Prévention

How to Minimize Pancreatic Cancer Risk [NY Times]

3.3 Prévention - Vaccins

Boys should be given HPV jab, says vaccine committee. Here’s what happens next. [Cancer Research UK]

HPV vaccination for males: effective and safe [BMC Blog]

JCVI statement: extending the HPV vaccination programme – conclusions []

3.8 Prévention - Alimentation

Low- or no-calorie soft drinks linked to improved outcomes in colon cancer [Yale News]

Diet soda and colon cancer: What you need to know [HealthNewsReview]

4.12 Biopsies liquides

Liquid Biopsy Controversy Rages On [Forbes]

A Blood Test For Early Detection Of Melanoma? Not Yet [Dr. Len]

Magnetized wire could be used to detect cancer in people [Stanford Medicine]

Stanford promotes a magnetized wire ‘to detect cancer in people.’ What you need to know [HealthNewsReview]

Why Consistent Testing Methods Are Crucial for Liquid Biopsies [University of Michigan]

4.2 Dép., diag. & prono. - Génome

Double Jeopardy: Gene-Sequencing Test Uncovers New Clues about a Defect Seen in Many Tumors [Memorial Sloan Kettering Cancer Center]

4.9 Dép., diag. & prono. - Sein

New approach to breast cancer screening — tailoring guidelines for each patient — may save lives and money, study says [STAT]

Computer simulation suggests risk-based breast screening could have benefits [Cancer Research UK]

No screening is better for women with low breast cancer risk, finds study [The Guardian]

Many Breast Cancer Patients Don’t Get Recommended Follow-Up, Study Finds [Wall Street Journal]

5. Traitements

Prostate cancer ultrasound treatment as effective as surgery or radiotherapy [Imperial College London]

Top oncologist to study effect of diet on cancer drugs [The Guardian]

5.1 Traitements - Pré-clinique

Overcoming resistance to a standard chemotherapy drug [Emory]

Mouse Study Links Immune Cells to Diarrhea Caused by Chemotherapy [NCI]

5.12 Immunothérapies

Can Age Affect Response to Immune Checkpoint Inhibitors? [NCI]

5.12.1 Immunothérapies - partenariats

Number 7? Celgene partner BeiGene joins the crowd with stellar PD-1/L1 data from a pivotal test [EndPoints]

5.12.2 Immunothérapies - CAR-T, thérapies cellulaires

Natural Killer Cells Prove Effective as a CAR Therapy in Mice [The Scientist]

Swift Gene-Editing Method May Revolutionize Treatments for Cancer and Infectious Diseases [NY Times]

5.12.3 Immunothérapies-combinaisons

FDA grants Breakthrough Therapy Designation for Roche’s Tecentriq in combination with Avastin as first-line treatment for advanced or metastatic hepatocellular carcinoma (HCC) [Roche]

5.12.5 Immunothérapies - Pharma

Roche’s Tecentriq in combination with pemetrexed and platinum-based chemotherapy reduced the risk of disease worsening or death in the initial treatment of people with advanced lung cancer [Roche]

Roche takes Tecentriq hit on survival data [Reuters]

Hitting cancer early: AstraZeneca's bid to outmaneuver rivals [Reuters]

5.12.6 Immunothérapies - AMM

Bristol-Myers Squibb’s Opdivo ® (nivolumab) + Low-Dose Yervoy ® (ipilimumab) is the First Immuno-Oncology Combination Approved for MSI-H/dMMR mCRC Patients Who Progressed Following Treatment with a Fluoropyrimidine, Oxaliplatin and Irinotecan [BMS]

5.12.8 Immunothérapies - Economie

CMS Abandonment of Outcomes-Based Payment Deal with Novartis is a Missed Opportunity [Harvard Law Blog]

Staggering Prices Slow Insurers’ Coverage Of CAR-T Cancer Therapy [KHN]

5.2 Pharma

Phase 3 Trial of NINLARO® (ixazomib) as Maintenance Therapy Met Primary Endpoint Demonstrating Statistically Significant Improvement in Progression-Free Survival in Patients with Multiple Myeloma Post-Transplant [Takeda]

Janssen Provides Update on IMBRUVICA® (ibrutinib) Phase 3 PHOENIX Trial in Newly Diagnosed Non-Germinal Center B Cell (Non-GCB) Subtype of Diffuse Large B-Cell Lymphoma (DLBCL) [Janssen]

CTI Biopharma's cancer drug fails late-stage trial, shares tumble [Reuters]

Mersana's cancer drug trial put on hold by FDA; shares halted [Reuters]

5.2.1 Pharma - Partenariats

Novartis punts a late-stage PI3K drug with a worrying safety profile to one of China’s upstart biotechs [EndPoints]

5.3 Traitements - FDA, EMA, NICE...

EMA identifies gaps in industry preparedness for Brexit [EMA]

EU drug regulators step up work to prepare for 'no deal' Brexit [Reuters]

FDA’s revolving door: Companies often hire agency staffers who managed their successful drug reviews [Science]

5.3.4 Traitements - AMM (FDA, EMA,...)

U.S. FDA Approves XTANDI® (enzalutamide) for the Treatment of Men with Non-Metastatic Castration-Resistant Prostate Cancer (CRPC) [Pfizer]

FDA approves first cancer drug through new oncology review pilot that enables greater development efficiency [FDA]

European Commission Approves Expanded Indication for Sprycel (dasatinib) to Include Treatment of Children with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase [BMS]

Agios scores its second new drug approval, ivosidenib heads to the AML market [EndPoints]

FDA approves ivosidenib for relapsed or refractory acute myeloid leukemia [FDA]

5.4 Traitements - Economie

Cancer drug for children recommended after becoming cost effective for NHS patients [NICE]

Life-extending immunotherapy approved on NHS for children with neuroblastoma [Cancer Research UK]

More people to be given dye to highlight brain tumours to surgeons say NICE [NICE]

Brain tumour chemotherapy now available to even more NHS patients [Cancer Research UK]

6. Lutte contre les cancers

NIH and Prostate Cancer Foundation launch large study on aggressive prostate cancer in African-American men [NCI]

Cancer drug movie strikes nerve in China, becomes box-office hit [Reuters]

A 6-year-old was diagnosed with an aggressive brain tumor. Then her little brother was, too. [Washington Post]

6.1 Observation

Diabetic women at greater risk of cancer than men, according to new study [The Telegraph]

Toward the control of cancer [CA: A Cancer Journal for Clinicians]

6.10 Politiques

It’s time to burst the biomedical bubble in UK research [The Guardian]

Leading International Cancer Organizations Call on United Nations Members to Reduce Disease Burden [ASCO]

6.10.1 Politiques (USA)

Merck Is Lowering Drug Prices. There’s a Catch. [NY Times]

Unpacking the bold — and the bluster — in Trump’s plan to bring down drug prices [STAT]

Merck lowers prices of some drugs after Trump calls out industry [Reuters]

Many Drugmakers Ignore Trump—and Raise Prices Anyway [Bloomberg]

Pfizer’s Announces it Will Defer Company’s Price Increases [Pfizer]

Trump Phones, And Pfizer Reverses Price Hikes. But Why? [Forbes]

6.12 Ethique

If you give your DNA and tissues to science, should you get a peek at what they might contain? [Science]

6.3 Associations/Fondations

Biomedical charity places major bet on ‘bold’ research to win bigger payoffs [Science]

6.5 Médecines alternatives

Mixing complementary therapy with standard cancer treatment could affect survival [Cancer Research UK]

Alternative medicine kills cancer patients, “complementary” edition [Science-Based Medicine]

Cancer patients who choose complementary medicine are twice as likely to die within seven years, study suggests [The Telegraph]

6.6 Publications

Dutch publishing giant cuts off researchers in Germany and Sweden [Nature]

Universities in Germany and Sweden Lose Access to Elsevier Journals [The Scientist]

6.7.2 Applis

Mobile Health Apps Get An FDA Push [Fortune]

6.9 Controverses

Pharma banks on cancer patients who are ‘determined to keep fighting’ [HealthNewsReview]

Foundation misleads vulnerable cancer patients with clickbait diet advice [HealthNewsReview]

Top cancer genetics professor quits job over bullying allegations [The Guardian]